Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 57s
Articles
A Multicentre, Open-Label, Randomised Controlled Clinical Trial to Assess the Efficacy and Safety of Appropriate Target Values for Lipid Management in Patients who Have Mild to Moderate Stenotic Lesions with High-Risk Plaques in Coronary Arteries: Study P
Published:
15 May 2020
Citation:
European Cardiology Review 2020;15:e47.
- Views:
10
- Downloads:
0
Atherosclerotic CVD Risk and Advanced Lipid Testing
Published:
15 July 2020
Citation:
European Cardiology Review 2020;15:e56.
- Views:
6
- Downloads:
0
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Published:
26 February 2020
Citation:
European Cardiology Review 2020;15:e04.
- Views:
5
- Downloads:
0
Adherence to Statin Therapy Drives Survival of Patients with Symptomatic Peripheral Artery Disease
Citation:
European Cardiology Review 2020;15:e30.
- Views:
4
- Downloads:
0